Use of Tolterodine extended Release in Overactive Bladder

نویسنده

  • Jacques Corcos
چکیده

Overactive bladder (OAB) is a common problem whose prevalence increases with advancing age and compromises ­health-related­quality­of­life.­Tolterodine­was­the­first­antimuscarinic­drug­specifically­designed­to­treat­OAB. Through­MEDLINE,­we­reviewed­articles,­standardization­reports­and­meeting­abstracts,­published­between­2001­and­2011,­on­the­efficacy and tolerability of Tolterodine extended release (ER). Our search terms included Tolterodine, extended release, overactive bladder, therapeutic­use,­efficacy,­tolerance,­and­adverse­events. Tolterodine­ER,­via­steady­drug­release­during­the­daytime,­gives­the­benefit­of­constant­serum­concentration­and­thus­better­efficacy­ and tolerability in comparison to Tolterodine immediate release, even in elderly patients with co-morbid conditions.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly

After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerabil...

متن کامل

Update on tolterodine extended-release for treatment of overactive bladder

Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-release (ER) is an efficacious and tolerable formulation of this class of medication. This review prov...

متن کامل

Treatment of Overactive Bladder Symptoms with Extended Release Fesoterodine Fumarate

Fesoterodine extended-release (brand name Toviaz) is a new competitive muscarinic receptor antagonist labeled for the treatment of overactive bladder (OAB). Here we have undertaken a substantial update to a systematic review evaluating the effects of fesoterodine in the treatment of OAB. Our results indicate that fesoterodine was found to have significant improvements in the management of OAB s...

متن کامل

A pharmacoeconomic model comparing two long-acting treatments for overactive bladder.

OBJECTIVE To compare the estimated first-line treatment costs of extended-release tolterodine versus controlled-release oxybutynin in patients with overactive bladder (OAB). METHODS We developed a decision-analysis model to estimate the patterns of treatment, resource consumption, and cost impact of treating OAB with either controlled-release oxybutynin or extended-release tolterodine as firs...

متن کامل

Newer agents for the management of overactive bladder.

The anticholinergics tolterodine and oxybutynin are well established in the management of overactive bladder. However, their activity at muscarinic receptors distant from the target site (i.e., bladder) produces anticholinergic side effects leading to poor tolerability. In 2004, trospium, solifenacin, and darifenacin were approved by the U.S. Food and Drug Administration for the treatment of ov...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012